Pazopanib and the treatment palette for soft-tissue sarcoma

Despite their common mesenchymal origin, soft-tissue sarcomas are heterogeneous and increasing knowledge of their molecular biology will drive future drug development.1 Effective targeting of KIT mutations by imatinib2 for gastrointestinal stromal tumours has been a notable success story in modern s...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2012-05, Vol.379 (9829), p.1854-1856
Main Author: Bramwell, Vivien HC
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Cancer
Cancer therapies
Chemotherapy
Clinical trials
Drug dosages
Female
Humans
Internal Medicine
Male
Molecular biology
Pyrimidines - therapeutic use
Quality of life
Sarcoma
Sarcoma - drug therapy
Soft Tissue Neoplasms - drug therapy
Sulfonamides - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite their common mesenchymal origin, soft-tissue sarcomas are heterogeneous and increasing knowledge of their molecular biology will drive future drug development.1 Effective targeting of KIT mutations by imatinib2 for gastrointestinal stromal tumours has been a notable success story in modern sarcoma therapy. Progression-free survival was chosen as the primary endpoint3 because a targeted agent would inhibit growth rather than cause tumour regression, and on the basis of an analysis of a large database of clinical trials by the European Organisation for Research and Treatment of Cancer, suggesting that 3-month progression-free survival of more than 40% for second-line chemotherapy correlates with clinical activity.5 Interpretation of a 3-month increase in progression-free survival in patients with heterogeneous soft-tissue sarcomas depends on accurate documentation of rapid progression before trial entry.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(12)60739-9